Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Dig Your Heels In: A Working Woman’s Series with YiDing Yu

YiDing Yu is the CMO at Olive, a practicing physician, published researcher, and serial entrepreneur. As a female in the healthcare and tech industries, she’s excited about the growth of women in healthcare. Yu said she grew up with a ton of interests. She knew she wanted to be a doctor when she was little….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Dig Your Heels In on MarketScale.

Share
Dig Your Heels In: A Working Woman’s Series with YiDing Yu

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

YiDing Yu is the CMO at Olive, a practicing physician, published researcher, and serial entrepreneur. As a female in the healthcare and tech industries, she’s excited about the growth of women in healthcare. Yu said she grew up with a ton of interests. She knew she wanted to be a doctor when she was little. But her love of politics and technology helped her combine her hobbies and develop beyond a practicing physician. Yu recalls she was driven by the thought of “how to solve the challenges I saw every day in healthcare” and eventually figured out that the “best way to solve that is working in systems.” And that’s how she got the tech bug.

According to an article published by the Harvard Business Review, for over 25 years, women have made up at least 40% of U.S. medical students, and in most recent years, more women than men have been enrolled in U.S. medical schools.

Yu lived this statistic, and she understands better than anyone that female enrollment in medical school is not reflective of women in leadership roles. Healthcare IT News found that despite the growth in women’s medical students, “only 25-30% percent of healthcare executives – and just 13% of CEOs – are female.” Yu has broken through that ceiling and has some empowering advice for how rising physicians can pave their way, and she reflects on what she learned from her development and male mentors.

Yu understands firsthand the struggle that women experience in the medical field. One of the first and most tangible things that she recommends is for aspiring healthcare leaders to protect their time for professional development. Women in medicine tend to put their patients first and professional development second. Yu recalls that her professional development occurred when she challenged herself and participated in special projects from administration to innovation. Once that starts, typically, development projects beget more development projects.

Be assertive and advocate for yourself. Chase that promotion, carve out time for professional development the way men are encouraged to, and source mentors who can strengthen your understanding of business strategy and financials. Always remember, you are the CEO of you. A recent study from Modern Healthcare News reported, “Typically, more men are exposed to finance and operations development than women, leading to lopsided leadership representation.”

Yu recalls learning to protect time to develop her leadership skills and forging her path by deviating from the style of male mentors. She says, “Every single role model who was in a position that I thought I might want was a man. Early in my career, I had to think through what is it like for a woman to be in that career? Do I have to act how they act?”

Yu urges women not to conform to the style of their male leaders if it isn’t natural for them. She recalls, “I felt like I was trying to dance a jig. Be enthusiastic but not too enthusiastic, assertive but not so assertive that you intimidate people.” Of course, professional behavior has to be upheld, but men and women operate differently. Successful leaders look different. They come in all different shapes, dialects, styles, and appearances.

Unfortunately, these trends will only continue until hospitals, corporations, and businesses around healthcare do not make a conscientious effort to drive a shift into more accurate representation.

In 2019 the US Census reported that a range of positions are dominated by women, but even where women outnumber men, like in nursing and speech pathology, they are not represented and excelling in leadership roles.

Of course, it takes time for generations to develop into leadership positions. Practitioners must challenge the status quo of academic structures and corporate structures to shift the fabric of the hierarchy and make it more inclusive.

To embrace diversity, companies have to start measuring it among their employees. Understanding the baseline and sharing it within creates conscious investment and accountability. Yu warns, “Without measurement, it’s easy to give yourself a pass.” At Olive, Yu has found that publishing that diversity measurement also acts as a gentle nudge for teams across the company.

In conclusion, Yu says it’s not just about the supply. It’s about how practitioners mentor and make leadership positions more accessible. She urges all professionals to understand that they have agency in this change. It may be as simple as reminding the acquisition team that you want to see more diversity.

For young professionals, know that agency lies in the ability to dedicate time to professional development. That likely means not picking up other physicians’ shifts to protect that growth. And finally, don’t be afraid to add flare into leadership. Many current leaders may not resemble females, but the female leadership style is bound to be just as successful.

Dig Your Heels In

Part of this channel

Dig Your Heels In

Business conversations for professionals who build on their own terms.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512